Trade BioMarin Pharmaceutical Inc - BMRN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023568% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001346% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 65.63 |
| Open | 65.87 |
| 1-Year Change | -31.62% |
| Day's Range | 65.87 - 66.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 31, 2024 | 65.63 | 0.34 | 0.52% | 65.29 | 66.03 | 65.12 |
| Dec 30, 2024 | 65.39 | -0.55 | -0.83% | 65.94 | 66.20 | 65.11 |
| Dec 27, 2024 | 66.64 | 0.45 | 0.68% | 66.19 | 67.18 | 65.99 |
| Dec 26, 2024 | 66.97 | 1.28 | 1.95% | 65.69 | 67.03 | 65.49 |
| Dec 24, 2024 | 66.38 | 0.65 | 0.99% | 65.73 | 67.01 | 65.05 |
| Dec 23, 2024 | 66.04 | 1.47 | 2.28% | 64.57 | 66.29 | 64.28 |
| Dec 20, 2024 | 65.43 | 1.49 | 2.33% | 63.94 | 66.16 | 63.81 |
| Dec 19, 2024 | 64.76 | 0.56 | 0.87% | 64.20 | 65.56 | 63.80 |
| Dec 18, 2024 | 64.45 | -2.26 | -3.39% | 66.71 | 67.27 | 64.45 |
| Dec 17, 2024 | 67.14 | 2.49 | 3.85% | 64.65 | 67.68 | 64.50 |
| Dec 16, 2024 | 65.45 | -0.98 | -1.48% | 66.43 | 67.09 | 65.32 |
| Dec 13, 2024 | 65.90 | 0.51 | 0.78% | 65.39 | 66.05 | 64.59 |
| Dec 12, 2024 | 66.05 | 0.62 | 0.95% | 65.43 | 66.62 | 65.04 |
| Dec 11, 2024 | 65.86 | -0.09 | -0.14% | 65.95 | 66.89 | 65.30 |
| Dec 10, 2024 | 66.17 | -0.34 | -0.51% | 66.51 | 66.98 | 65.93 |
| Dec 9, 2024 | 66.70 | 0.81 | 1.23% | 65.89 | 67.80 | 65.89 |
| Dec 6, 2024 | 66.65 | 0.37 | 0.56% | 66.28 | 66.97 | 65.50 |
| Dec 5, 2024 | 66.10 | 0.22 | 0.33% | 65.88 | 66.81 | 65.25 |
| Dec 4, 2024 | 66.30 | 3.43 | 5.46% | 62.87 | 66.63 | 62.50 |
| Dec 3, 2024 | 62.94 | -1.72 | -2.66% | 64.66 | 64.86 | 62.93 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.
Equity composition
Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.
| Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
News
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com